The Global Colorectal Cancer Market was worth $15.3 billion in 2019 and estimated to be growing at a CAGR of 2.63%, to reach $17.4 billion by 2024. Though there has been substantial development in science and technology to combat cancer, it continues to threaten lives across the globe. Colorectal cancer, the third most common type of cancer is fast becoming a horrible reality for many.
Colorectal cancer is a consequence of unrestrained cell growth that occurs in the appendix, colon, and the rectum region. Some of the generally seen symptoms of colorectal cancer are blood in the stool, weight loss, fatigue, and irregular bowel movements. Colorectal cancer is identified with a biopsy, which then followed by medical imaging to know its extent. Depending on the stage and how much the cancer has expanded, a combination of radiation therapy, chemotherapy, and targeted therapy is recommended by most oncologists.
The growth of the Global Colorectal Cancer Market is mainly driven by factors such as rise in pipeline colorectal cancer screening tests, aging population, increasing awareness, and government policies to provide better care for Colorectal Cancer. However, high costs of screening tests and poor availability of proper cancer care in the emerging regions are hindering the growth of the market.
The Global Colorectal Cancer market is segmented based on Diagnosis and Treatment. The market for Colorectal Cancer, on the basis of Diagnosis is segmented into Digital Rectal Examination, Faecal Occult Blood Test, Flexible Sigmoidoscopy, Colonoscopy, Virtual Colonoscopy. On the basis of Treatment, the global Colorectal Cancer market is segmented into Surgery and Radiation Therapy, Chemotherapy, Targeted Therapies, Resistance to Pharmacological Therapies.
The market has also been geographically segmented into North America, Europe, Asia-Pacific and the Rest of the World. North America accounted for the largest share in the global Colorectal Cancer market followed by Asia-Pacific and Europe. However, The Asia-Pacific region is projected to grow at the highest CAGR during the forecast period due to reasons such as increasing participation of several private & public establishments to organize awareness programs on Colorectal Cancer.
The major companies dominating the Colorectal Cancer market are Abbott Diagnostics, Alere, Beckman Coulter, Clinical Genomics, Companion Dx, Hoffmann La Roche, Debiopharm Group, Vaccinogen BD.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Diagnosis
5.1.1 Digital Rectal Examination
5.1.2 Faecal Occult Blood Test
5.1.3 Flexible Sigmoidoscopy
5.1.4 Colonoscopy
5.1.5 Virtual Colonoscopy
5.2 By Treatment
5.2.1 Surgery and Radiation Therapy
5.2.2 Chemotherapy
5.2.3 Targeted Therapies
5.2.4 Resistance to Pharmacological Therapies
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Diagnostics
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Alere
8.3 Beckman Coulter
8.4 Clinical Genomics
8.5 Companion Dx
8.6 Hoffmann La Roche
8.7 Debiopharm Group
8.8 Vaccinogen BD
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
